Physician profile

Babar Ali

Interventional Cardiology · Takoma Park, MD

NPI 1952505877

$9,110.39

in general payments reported to CMS, 2019-2025

37 companies · $1,114 in 2025

The $1,114 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,435.88
Travel and Lodging$288.33
Education$94.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Philips North America LLC $1,565.31 2019-2025 Mcot
Cook Medical LLC $1,191.32 2019-2025 Advance, Zilver Ptx, Zilver Vena
Surmodics, INC. $784.03 2023 Sublime 014 Rx Pta Balloon Dilatation Catheter, Sublime Microcatheter, 014, 65cm, Straight, Sublime Microcatheter, 014, 65cm, Angle
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $620.18 2019-2025 Lifevest
Medtronic, INC. $532.99 2021-2024 Micra, Venaseal
Boston Scientific Corporation $472.88 2019-2025 Avvigo Guidance System, Bodyguardian
Amgen INC. $430.74 2019-2025 Repatha, Repatha
Abbott Laboratories $386.25 2019-2025 Diamondback Peripheral, Esprit, Emboshield Nav6
Novartis Pharmaceuticals Corporation $371.38 2019-2025
Medtronic Vascular, INC. $315.17 2019
Terumo Medical Corporation $286.77 2019-2022
Astrazeneca Pharmaceuticals LP $272.37 2019-2025 Wainua
Pfizer INC. $222.31 2019-2025
E.R. Squibb & Sons, L.L.C. $197.65 2019-2025 Camzyos, Eliquis
Janssen Pharmaceuticals, INC $191.51 2019-2021
Show all 37 companies
CompanyGeneral paymentsYearsTop products
W. L. Gore & Associates, INC. $127.39 2019-2025 Gore Viabahn Vbx Balloon Expandable Endo
Alnylam Pharmaceuticals INC. $120.26 2020-2025 Amvuttra
Dexcom, INC. $119.51 2023 Dexcom G6 Transmitter
Actelion Pharmaceuticals US, INC. $94.99 2024 Uptravi, Opsumit
Bayer Healthcare Pharmaceuticals INC. $75.82 2024-2025
Merck Sharp & Dohme LLC $71.58 2024 Verquvo
Amarin Pharma, INC. $70.11 2020-2021
Silk Road Medical, INC. $63.38 2019-2022
Atricure, INC. $59.02 2024
Baxter Healthcare $58.87 2024 Hillrom - Carnation Ambulatory Monitor
Sanofi-Aventis U.S. LLC $52.19 2019
Biotronik INC. $51.94 2019-2021
Penumbra, INC. $45.71 2025 Penumbra System
Astellas Pharma US INC $38.96 2019
Shockwave Medical, INC $37.51 2019-2021
Boehringer Ingelheim Pharmaceuticals, INC. $32.95 2020
Cardiovascular Systems INC. $31.87 2019-2021
Regeneron Healthcare Solutions, INC. $31.05 2019
Arbor Pharmaceuticals, INC. $29.72 2019-2020
Kowa Pharmaceuticals America, INC. $24.78 2021
Edwards Lifesciences Corporation $16.52 2019
Kiniksa Pharmaceuticals International, Plc $15.40 2024 Arcalyst

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Babar Ali

$9,110.39

in general payments reported 2019-2025

Years
2019-2025
Top company
Philips North America LLC
Context
The $1,114 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).

https://glasscript.com/doctor/361524/babar-ali

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.